Original Source(s)
Related Content
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
July 1, 2026
-
1 min
Renowned medical oncologist shares key takeaways from ASCO 2026
Farshid Dayyani, MD, PhD shared his key takeaways on emerging developments in gastrointestinal oncology at ASCO 2026.
June 25, 2026
-
1 min
2026 AACR Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.
June 17, 2026
-
1 min
